Experlytics proudly announces the release of a bespoke electronic data capture platform with pioneering analytical tools for Lund Melanoma Study Group (LMSG). The platform will manage all data capture for the BioMEL project for a duration of 5 + years. Apart from being one of the most complex productions undertaken by Experlytics, the platform incorporates novel features such as a cross platform statistical viewer and an artificial intelligence powered factor weighting analytics tool.
The background of the collaboration is rooted in the visionary research by Lund Melanoma Study Group. LMSG is a translational research group within melanoma research with the ambitions of finding the special characteristics showing the progression of malignant melanoma and how new medical treatments can suit different subtypes of malignant melanoma.
“We carefully selected Experlytics as a vendor for our study platform based on their impressive track record architecting robust and cutting-edge multicenter study systems. We were curious how they would manage the many complexities involved in our set up and tailor the platform to our needs. Based on our experience with the platform we are confident we made the right choice and this feeling has been verified by prompt and responsive service”, said Professor Christian Ingvar, consultant surgeon at Skåne University Hospital in and responsible for the BioMEL study.
“The BioMEL study and the ambitious initiative of the LMSG are profound and pressing to our society and we are equally pleased and proud to make a small contribution. The platform for BioMEL stands out in its massive scope of work including highlights such as managing the patient photo documentation and the world premiere of an integrated factor-weighting tool for optimal data collection. Besides the great work together with LMSG, Experlytics has enjoyed a very smooth cooperation with Lixion in producing the fully responsive public web site at biomel.org”, said Mattias Paulsson, CEO & Partner of Experlytics.
About Lund Melanoma Study Group
Lund Melanoma Study Group (LMSG), founded by epidemiologist/ clinical oncologist Professor Håkan Olsson and the surgeon Professor Christian Ingvar in early 1980-ties, is a multidisciplinary group in melanoma research located in Medicon Village Lund, Helsingborg General Hospital, Skåne University Hospital in Malmö and Lund. LMSG has researching clinicians including surgeons, oncologists, epidemiologists, dermatologists and pathologists together with molecular biologists, statisticians, PhD students, researching medical students, secretaries and research nurses. LMSG’s mission is to answer the questions; WHO, WHY and HOW individuals get melanoma.